Treatment schedule. Escalating doses of oral lenalidomide (10, 15, 20, or 25 mg) were administered to 4 patient cohorts (n = 3-6) from days 1 to 21 in cycle 1 and day 2 to 22 in cycles 2 through 6. Obinutuzumab (1000 mg) IV was administered on days 8, 15, and 22 of cycle 1 and day 1 of cycles 2 through 6 (total of 8 infusions). Cycles are 28 days in length.